> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-205/
- Published: 2018-11-25T12:00:00.000Z
- Updated: 2026-09-15T00:46:27.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142890

[**Info Collection on Drug Labeling Content/Format**](https://www.fdaweb.com/info-collection-on-drug-labeling-content-format/)  
*Federal Register* notice: FDA submits to OMB an information collection extension entitled “Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products.” 11/21/2018

[**Teva Used Priority Voucher for Migraine Drug**](https://www.fdaweb.com/teva-used-priority-voucher-for-migraine-drug/)  
*Federal Register* notice: FDA announces an approval for Teva’s Ajovy (fremanezumab-vfrm) injection for preventing migraine in adults under a redeemed priority review voucher. 11/21/2018

[**New Info Collection on Cosmetic GMP Survey**](https://www.fdaweb.com/new-info-collection-on-cosmetic-gmp-survey/)  
*Federal Register* notice: FDA submits to OMB a new information collection entitled “Survey of Current Manufacturing Practices for the Cosmetics Industry.” 11/20/2018

[**Comments Sought on Drug Sponsor Disseminated Software**](https://www.fdaweb.com/comments-sought-on-drug-sponsor-disseminated-software/)  
*Federal Register* notice: FDA seeks comments on a proposed framework for regulating software applications disseminated by or on behalf of drug sponsors for use with one or more of their prescription drug products. 11/20/2018

[**Info Collection Extension for Biosimilar Applications**](https://www.fdaweb.com/info-collection-extension-for-biosimilar-applications/)  
*Federal Register* notice: FDA submits to OMB an information collection extension for “General Licensing Provisions; Section 351(k) Biosimilar Applications.” 11/19/2018

[**47 Drugs Listed Not Withdrawn Due to Safety/Efficacy**](https://www.fdaweb.com/47-drugs-listed-not-withdrawn-due-to-safety-efficacy/)  
*Federal Register* notice: FDA determines that 47 drug products it is listing were not withdrawn from sale for reasons of safety or effectiveness. 11/19/2018